Seizures during antidepressant treatment in psychiatric inpatients - Results from the transnational pharmacovigilance project " arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008

Psychopharmacology

Volumn 230, Issue 2, 2013, Pages 191-201

  Koster M ^c   Grohmann, R ^a   Engel, R R ^a   Nitsche, M A ^b   Ruther E ^a   Degner, D ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c NONE   (Switzerland)

Author keywords

Adverse drug reaction; Antidepressants; Grand mal seizure; Pharmacovigilance; Seizure; Side effects

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; NORTRIPTYLINE; PAROXETINE; PRIMIDONE; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EPILEPSY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MIDDLE AGED; MONOTHERAPY; MOOD DISORDER; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEIZURE; TONIC CLONIC SEIZURE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; EPILEPSY, TONIC-CLONIC; FEMALE; GERMANY; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PHARMACOVIGILANCE; RISK; YOUNG ADULT;

EID: 84891769409     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3281-8     Document Type: Review

References (67)

1. Alper K, Schwartz K, Kolts R, Khan A (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62(4):345-354
2. Anderson I, Ferrier I, Baldwin R, Cowen P, Howard L, Lewis G, Matthews K, McAllister-Williams R, Peveler R, Scott J, Tylee A (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22(4):343-396
3. Bauer M, Bschor T, Pfennig A, Whybrow P, Angst J, Versiani M, Möller H, W. T. F. o. U. D. Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8(2):67-104
4. Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M (2008) Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf 31(11):1017-1026
5. Bonnet U (2003) Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 9(1):97-140
6. Boyer E, Shannon M (2005) The serotonin syndrome. N Engl J Med 352(11):1112-1120
7. Buckley N, McManus P (2002) Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325(7376):1332-1333
8. Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse A (2004) Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 184:41-47
9. Clinckers R, Gheuens S, Smolders I, Meurs A, Ebinger G, Michotte Y (2005) In vivo modulatory action of extracellular glutamate on the anticonvulsant effects of hippocampal dopamine and serotonin. Epilepsia 46(6):828-836
10. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343:d4551
11. Cowen P, Ogilvie A, Gama J (2005) Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Curr Med Res Opin 21(3):345-356
12. Davidson J (1989) Seizures and bupropion: a review. J Clin Psychiatry 50(7):256-261
13. Davidson J (2010) Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 71(E1):e04
14. Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel R, Schmidt L (2004) Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 37(Suppl 1):S39-45
15. Dessain E, Schatzberg A, Woods B, Cole J (1986) Maprotiline treatment in depression. A perspective on seizures. Arch Gen Psychiatry 43(1):86-90
16. Dunner D, Zisook S, Billow A, Batey S, Johnston J, Ascher J (1998) A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 59(7):366-373
17. Eyer F, Stenzel J, Schuster T, Felgenhauer N, Pfab R, von Bary C, Zilker T (2009) Risk assessment of severe tricyclic antidepressant overdose. Hum Exp Toxicol 28(8):511-519
18. Fava G, Tomba E (2010) New modalities of assessment and treatment planning in depression: the sequential approach. CNS Drugs 24(6):453-465
19. Favale E, Audenino D, Cocito L, Albano C (2003) The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 12(5):316-318
20. Gartlehner G, Thieda P, Hansen R, Gaynes B, Deveaugh-Geiss A, Krebs E, Lohr K (2008) Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 31(10):851-865
21. Gelzer J (1986) Limits to chemotherapy of depression. Psychopathology 19(Suppl 2):108-117
22. Goldberg JF, Brooks JO, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME (2009) Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 70(2):155-162
23. Goodwin G, Anderson I, Arango C, Bowden C, Henry C, Mitchell P, Nolen W, Vieta E, Wittchen H (2008) ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 18(7):535-549
24. Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt L (2004) The AMUP study for drug surveillance in psychiatry - a summary of inpatient data. Pharmacopsychiatry 37(Suppl 1):S16-26
25. Grunze H, Vieta E, Goodwin G, Bowden C, Licht R, Möller H, Kasper S, W. T. F. O. T. G. F. B. Disorders (2010) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 11(2):81-109
26. Haddad P, Dursun S (2008) Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 23(Suppl 1):15-26
27. Hauser W, Annegers J, Kurland L (1993) Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34(3):453-468
28. Henry J, Alexander C, Sener E (1995) Relative mortality from overdose of antidepressants. BMJ 310(6974):221-224
29. Hunziker M, Suehs B, Bettinger T, Crismon M (2005) Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 27(8):1126-1143
30. Isbister G, Bowe S, Dawson A, Whyte I (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42(3):277-285
31. Jobe P, Browning R (2005) The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 7(4):602-619
32. Johnston J, Lineberry C, Ascher J, Davidson J, Khayrallah M, Feighner J, Stark P (1991) A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 52(11):450-456
33. Kanner A (2007) Epilepsy and mood disorders. Epilepsia 48(Suppl 9):20-22
34. Kumlien E, Lundberg P (2009) Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 19(2):69-73
35. Lanes T, Ravaris CL (1993) Prolonged ECT seizure duration in a patient taking trazodone. Am J Psychiatry 150(3):525
36. Lowry M, Dunner F (1980) Seizures during tricyclic therapy. Am J Psychiatry 137(11):1461-1462
37. Maramattom B (2006) Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures. Neurology 66(5):773-774
38. Melani F, Rosati E, Chiocchetti B, Muscas G (2009) Antidepressant- associated myoclonic status in a patient with symptomatic generalized epilepsy: does risk occur with therapeutic doses? Epilepsy Behav 14(4):681-683
39. Menchetti M, Gozzi B, Saracino M, Mercolini L, Petio C, Raggi M (2009) Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry 10(4 Pt 2):385-389
40. Montgomery S (2005) Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 59(12):1435-1440
41. Montgomery S (2008) Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 13(7 Suppl 11):27-33
42. Mottram P, Wilson K, Strobl J (2006) Antidepressants for depressed elderly. Cochrane Database Syst Rev(1): CD003491
43. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser W (2005) Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 4(10):627-634
44. Olfson M, Marcus S, Tedeschi M, Wan G (2006) Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 163(1):101-108
45. Papakostas G (2010) The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry 71(E1):e03
46. Peck A, Stern W, Watkinson C (1983) Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 44(5 Pt 2):197-201
47. Pinder R, van Delft A (1983) Pharmacological aspects of mianserin. Acta Psychiatr Scand Suppl 302:59-71
48. Pisani F, Oteri G, Costa C, di Raimondo G, di Perri R (2002) Effects of psychotropic drugs on seizure threshold. Drug Saf 25(2):91-110
49. Rosenstein D, Nelson J, Jacobs S (1993) Seizures associated with antidepressants: a review. J Clin Psychiatry 54(8):289-299
50. Ross S, Williams D (2005) Bupropion: risks and benefits. Expert Opin Drug Saf 4(6):995-1003
51. Rush A, Trivedi M, Wisniewski S, Nierenberg A, Stewart J, Warden D, Niederehe G, Thase M, Lavori P, Lebowitz B, McGrath P, Rosenbaum J, Sackeim H, Kupfer D, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry 163(11):1905-1917
52. Schmitz B (2002) Antidepressant drugs: indications and guidelines for use in epilepsy. Epilepsia 43(Suppl 2):14-18
53. Serna M, Cruz I, Real J, Gascó E, Galván L (2010) Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 25(4):206-213
54. Sharma A, Goldberg M, Cerimele B (2000) Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40(2):161-167
55. Singer PP, Jones GR (1997) An uncommon fatality due to moclobemide and paroxetine. J Anal Toxicol 21(6):518-520
56. Specchio LM, Iudice A, Specchio N, la Neve A, Spinelli A, Galli R, Rocchi R, Ulivelli M, de Tommaso M, Pizzanelli C, Murri L (2004) Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 27(3):133-136
57. Spigset O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R (1997) Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 96(5):379-384
58. Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry S, Kunkel S (2009) Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med 27(8):911-915
59. Tasini M (1986) Complex partial seizures in a patient receiving trazodone. J Clin Psychiatry 47(6):318-319
60. Taylor D (2010) Venlafaxine and cardiovascular toxicity. BMJ 340:c411
61. Tutka P, Mróz T, Klucha K, Piekarczyk M, Wielosz M (2005) Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res 64(1-2):13-22
62. Vanpee D, Laloyaux P, Gillet JB (1999) Seizure and hyponatraemia after overdose of trazadone. Am J Emerg Med 17(4):430-431
63. Waring W, Gray J, Graham A (2008) Predictive factors for generalized seizures after deliberate citalopram overdose. Br J Clin Pharmacol 66(6):861-865
64. White N, Litovitz T, Clancy C (2008) Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 4(4):238-250
65. Whyte I, Dawson A, Buckley N (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96(5):369-374
66. Yatham L, Kennedy S, Schaffer A, Parikh S, Beaulieu S, O'Donovan C, MacQueen G, McIntyre R, Sharma V, Ravindran A, Young L, Young A, Alda M, Milev R, Vieta E, Calabrese J, Berk M, Ha K, Kapczinski F (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11(3):225-255
67. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda CM, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M (2013) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15(1):1-44